title: TIMI 3 flow after primary angioplasty is an important predictor for outcome in patients with acute myocardial infarction.
abstract: BACKGROUND
  Growing evidence suggests that poor coronary blood flow after primary percutaneous coronary intervention (PCI) is associated with unfavorable clinical out-come. We retrospectively evaluated data from our single center "real world patients" database of patients undergoing primary PCI to determine differences in clinical and angiographic patterns in patients with or without restoring thrombolysis in myocardial infarction (TIMI) flow 3.
  
  
  RESULTS
  Between 2001 and 2006, 500 patients underwent primary PCI for STEMI. In 430 patients, post-interventional TIMI flow 3 could be established. In this group, in-hospital mortality was significant lower (6.4% Vs. 32.9%; P < 0.0001), left ventricular ejection fraction was better (51.3 Vs. 44.2%; P < 0.0001), and prehospital fibrinolytic therapy (6.3% Vs. 14.3%; P = 0.015), cardiogenic shock (10.9% Vs. 24.3%; P = 0.002) and use of intra-aortic balloon pump were all more unlikely (5.8% Vs. 11.4%; P = 0.045) compared to patients with TIMI flow < or = 2. In patients with post-interventional TIMI flow < or = 2 the left anterior descending coronary artery (LAD) was significantly more often seen as the target vessel (54.3% Vs. 44.6%; P = 0.039). A regressions analysis showed that predictors leading to such flow patterns are diabetes (P = 0.013), pre-hospital fibrinolytic therapy (P = 0.017), cardiogenic shock (P = 0.002) and a 3-vessel disease (P = 0.003). After 6 months, patients without restored normal TIMI flow had worse New York Heart Association functional class (NYHA), and had to undergo repeat coronary angiography more often.
  
  
  CONCLUSIONS
  Post-interventional TIMI flow < or = 2 is strongly associated with adverse out-come during hospitalization and after 6 months following hospitalization.
authors.affiliation: Cardiovascular Division, General Hospital Linz, Krankenhausstrasse 9, Linz, Austria. juergen.kammler@akh.linz.at
authors.forename: Juergen
authors.initials: J
authors.lastname: Kammler
authors.forename: Alexander
authors.initials: A
authors.lastname: Kypta
authors.forename: Robert
authors.initials: R
authors.lastname: Hofmann
authors.forename: Klaus
authors.initials: K
authors.lastname: Kerschner
authors.forename: Michael
authors.initials: M
authors.lastname: Grund
authors.forename: Kurt
authors.initials: K
authors.lastname: Sihorsch
authors.forename: Clemens
authors.initials: C
authors.lastname: Steinwender
authors.forename: Thomas
authors.initials: T
authors.lastname: Lambert
authors.forename: Wolfram
authors.initials: W
authors.lastname: Helml
authors.forename: Franz
authors.initials: F
authors.lastname: Leisch
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D003326:Coronary Circulation; D016208:Databases, Factual; D048909:Diabetes Complications / Q000453:epidemiology; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D011237:Predictive Value of Tests; D012044:Regression Analysis; D012086:Reoperation / Q000706:statistics & numerical data; D012189:Retrospective Studies; D012307:Risk Factors; D012770:Shock, Cardiogenic / Q000209:etiology / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents